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Advanced glycation endproducts and plaque
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Online publish-ahead-of-print 31 October 2013
This editorial refers to ‘Higher levels of advanced glycation
endproducts in human carotid atherosclerotic plaques are
associated with a rupture-prone phenotype’†, by N.M.J.
Hanssen et al., on page 1137
Despite clear advances in the treatment of vascular disease, we are
still far from the understanding and valid assessment of the natural
history of atherosclerotic plaque. Several studies have shown that
the vulnerable plaque is the main culprit for ischaemic cardiac and
cerebral events, but reliable indicators of plaque instability remain
elusive in clinical practice.1 This aspect deserves attention since
rupture of carotid plaques explains at least 15–20% of all ischaemic
strokes or transient ischaemic attacks.2 Over 15 million people per
year suffer strokes worldwide, resulting in 5 million deaths, and an add-
itional 5 million remain permanently disabled.2 Treatment of carotid
artery stenosis by endoarterectomy or stenting can significantly
reduce stroke risk, but it is also accompanied by surgery-related mor-
bidityandmortality.1,2Moreover,notall carotidarteryplaquesbecome
symptomatic and result in ischaemic events. In this perspective, the
identification of carotid plaques at high risk for neurological events is
fundamental to the selection of patients for vascular interventions.
Different processes involved in the progression of atherosclerotic
lesions have been associated with plaque vulnerability.3 Previous
seminal investigations have clearly shown that inflammation, prote-
olysis, and apoptosis are major drivers of plaque complexity and fra-
gility.3 Pathological featuresof unstableplaques are representedbyan
atheromatous thin fibrous cap, large necrotic core, infiltration of in-
flammatory cells, and scarce calcification. Despite available imaging
techniques providing an exhaustive macroscopic characterization
of the plaque, the innermechanisms involved remain tobe largelyelu-
cidated and characterization of the molecular processes is achieved
only at post-operative or post-mortem examination.1 The assess-
ment of early markers of plaque vulnerability is an attractive challenge
to select candidates for mechanism-based therapeutic strategies.
Among different biomarkers, advanced glycation endproducts
(AGEs) have been linked to the atherosclerotic process and are
emerging as a novel signature of atherosclerotic disease.4 AGEs are
a large family of extensively sugar-modified proteins which can be
formed in plaques as a consequences of increased metabolic activ-
ity.1,4 It is well established that AGEs are present in atherosclerotic
lesions.5 Of note, inhibition of synthesis of AGEs prevents or attenu-
atesatherosclerosis inexperimentalmodels.4,5Despite the linkbetween
AGEs and atherosclerosis, their precise role in the context of athero-
sclerotic plaque remains unclear.
Hanssen and colleagues have now shown that AGE accumulation
may represent an indicator of plaque vulnerability.6 The authors
found that two major AGEs, the methylglyoxal-derived 5-hydro-
5-methylimidazolone (MG-H1) and N1 (carboxylmethyl)lysine
(CML), measured with tandem mass spectrometry, were significantly
higher in symptomatic as compared with asymptomatic carotid
plaques. MG-H1 and CML were associated with increased levels of
the inflammatory cytokines interleukin-8 (IL-8) and monocyte
chemoattractant protein 1 (MCP-1), as well as with higher activity
of matrix metalloproteinase 9 (MMP-9), an important modulator of
plaque collagen content. Immunohistochemistry showed that AGE
accumulation occurs in macrophages, is mostly confined to
hypoxic regions of the necrotic core, and co-localizes with the apop-
totic marker caspase-3 (Figure 1). Interestingly, gene expression of
glyoxalase-1 (GLO1), the most important methylglyoxal-detoxifying
enzyme, was decreased in vulnerable as compared with stable
plaques. A provocative finding of the present work is that MG-H1
and CML were independently associated with a vulnerable plaque
phenotype, regardless of diabetes. History of diabetes did not
affect the link between AGEs and plaque inflammation, and no corre-
lations were found between fasting glycaemia and AGE levels, even
after adjustment for glucose-lowering drugs. These findings suggest
the possibility that AGEs can also be considered markers of plaque
inflammation and instability in non-diabetic individuals. Indeed, the
major determinant of intraplaque protein glycation is the high meta-
bolic activity of macrophages, leading to enhanced D-glucose uptake
and subsequent formation of AGEs (Figure 1). This assumption is sup-
ported by the demonstration that positron emission tomography
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(PET)-based uptake of the glucose analogue [18F]fluorodeoxyglu-
cose (18FDG) is enhanced in symptomatic carotid arteries of non-
diabetic patients.7 Unfortunately, glycated haemoglobin (Hb1Ac)
was not available in the study by Hanssen et al.6 and it is not possible
to rule out that chronic hyperglycaemia might also affect intraplaque
glucose content, leading to a further extent of protein glycation.
Another interesting finding of this study is that hypoxia within the
necrotic core may trigger AGE formation in macrophages (Figure 1).
Indeed, MG-H1 and CML co-localized with macrophage-rich and
hypoxic regions, as assessed by pimonidazole staining. To investigate
the link between intraplaque hypoxia and AGE synthesis further,
MG-H1 and CML levels were measured in human monocytes after
exposure to low oxygen concentrations (0.2%). Interestingly, in
vitro hypoxia enhanced AGE formation mostly via increased methyl-
glyoxal (MGO) levels and GLO1 down-regulation (Figure 1). These
findings are in line with recent work showing that GLO1-dependent
detoxification is an important defender of vascular homeostasis.8
However, a previous study from the same group showed that poly-
morphisms in the GLO1 gene are not associated with vascular com-
plications in two Dutch cohorts of patients with normal glucose
metabolism, impaired glucose tolerance, and type 2 diabetes melli-
tus.9 Therefore, the exact contribution of GLO1 to human
Figure 1 Role of advanced glycation endproducts (AGEs) in plaque vulnerability. The AGEs MG-H1 and CML are synthesized in macrophages of
vulnerable carotid plaques due to high glucose uptake. MG-H1 and CML accumulation mostly occurs in the hypoxic region of the necrotic core.
Inflammatory cytokines IL-8 and MCP-1 as well as MMP-9 trigger AGE formation and subsequent cell apoptosis via activation of caspase-3. On
the other hand, down-regulation of the methylglyoxal-detoxifying enzyme GLO1 contributes to AGE accumulation. CML, Ne (carboxylmethyl)ly-
sine; GLO1, glyoxalase-1; IL-8, interleukin-8; MCP-1, monocyte chemoattractant protein-1; MG-H1, 5-hydro-5-methylimidazolone; MMP-9,
metalloproteinase-9; VSMCs, vascular smooth muscle cells.
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atherosclerosis remains to be elucidated. In this regard, Hanssen et al.
propose that AGE accumulation may be the effect and not the cause
of plaque inflammation.6 Indeed, the inflammatory in vitro effect of
tumour necrosis factor-a (TNF-a) on IL-8, MCP-1, or MMP-9 is
not dependent on AGEs because the AGE inhibitor aminoguanidine
reduced MGOandAGE formation but didnot affect IL-8,MCP-1, and
MMP-9 expression. Moreover, incubation of monocytes with CML
or MGO did not increase the secretion of IL-8, MCP-1, and
MMP-9.6 These findings are in contrast to previous work showing
that AGE–RAGE (AGE receptor) signalling leads to an increased oxi-
dative burst via NADPH oxidase and mitogen-activated protein
kinases (ERK 1/2) with subsequent activation of nuclear factor-kB
(NF-kB) and transcription of inflammatory genes.10 Thus, the AGE
content in the plaque may be the result of a vicious cycle involving in-
flammation, oxidative stress, AGEs, and NF-kB activation. In contrast,
ifAGEs are just a consequence of plaque inflammation theycannot be
considered early biomarkers of the atherosclerotic process but
rather a mirror of the inflammatory milieu. A further interpretation
is that the highly antigenic nature of CML primarily triggers an inflam-
matory response in the subendothelial layer, favouring the athero-
sclerotic process. This latter hypothesis may not be that unrealistic
since autoimmune responses have been postulated as potential
drivers of vascular inflammation.11 In line with this interpretation,
the RAGEs were not up-regulated in vulnerable plaques, suggesting
that AGE–RAGE interaction may be less relevant than intracellular
accumulation of AGEs. However, such a provocative finding of
normal RAGE expression in unstable plaques deserves further inves-
tigation. A phase II clinical trial demonstrated that pharmacological
AGE degradation by the cross-link breaker ALT-711 reduced arterial
pulse pressure and improved the compliance of large arteries, two
important pre-atherosclerotic features.12 Another study with benfo-
tiamine prevented both macro- and microvascular endothelial dys-
function and oxidative stress induced by an AGE-rich meal.13
Moreover, the combined use of benfotiamine and a-lipoic acid nor-
malized the elevated AGEs levels and blocked the enhancement of
hexosamine-modified protein formation in monocytes of patients
with type 1 diabetes.14 Based on these studies, AGE formation may
represent an upstream event triggering vascular inflammation, oxida-
tive stress, and eventually plaque instability.
In summary, Hanssen and colleagues demonstrate for the first time
an intriguing link between AGEs and plaque phenotype. These results
imply that AGEs may represent a putative biomarker of rupture-
prone plaques, regardless of diabetes. However, several considera-
tions should be taken into account before considering this cardiovas-
cular risk stratification approach. While AGE levels in the plaque
strongly correlate with a vulnerable phenotype, it remains unclear
whether plasma or skin-derived AGEs similarly reflect this associ-
ation. This aspect has important clinical implications since the assess-
ment of AGEs in the carotid arteries can be performed only after
post-operative examination and it is not applicable as a screening
tool. In this context, previous work suggested that measuring AGEs
in skin using autofluorescence may provide important information
on risk stratification in diabetic patients. This study involving 972 dia-
betic patients showed that the addition of skin AGEs to the UKPDS
risk engine resulted in re-classification of 27% of the patients from
the low- to the high-risk group.15 The 10-year cardiovascular event
rate was higher in patients with a UKPDS score .10% when skin
AGEs were above the median (56% vs. 39%).
Undoubtedly, this work has shed some light on the intriguing issue
of AGE levels as early biomarker of plaque instability. However, add-
itional pre-clinical studies are mandatory to understand whether
AGE inhibition may prevent or delay atherosclerotic complications.
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